Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Childhood AML study of homoharringtonine versus anthracycline-based treatment
ChiCTR-IIR-17013614Phase 3Recruiting
- Sponsor
- Shanghai Children's Medical Center
- Start
- Nov 2017
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of homoharringtonine in acute myeloid leukemia (AML) (2 arms), sponsored by Shanghai Children's Medical Center. Primary endpoint: Survival. Started Nov 2017; status: recruiting.
02
Drugs
homoharringtonine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR-IIR-17013614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-17013614.